4//SEC Filing
Myrexis, Inc. 4
Accession 0000921895-21-002138
CIK 0000727510operating
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 6:07 PM ET
Size
16.5 KB
Accession
0000921895-21-002138
Insider Transaction Report
Form 4
COUCHMAN JONATHAN
10% OwnerOther
Transactions
- Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−50,000$19,490→ 350,000 total(indirect: By Couchman Family Fund) - Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−57,500$22,414→ 2,043,024 total(indirect: By Xstelos Corp.)
Holdings
- 4,717,666(indirect: By Jonathan Couchman)
Common Stock, $0.01 par value
- 633,264(indirect: By Myrexis, Inc.)
Common Stock, $0.01 par value
Couchman Family Fund
Other
Transactions
- Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−50,000$19,490→ 350,000 total(indirect: By Couchman Family Fund) - Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−57,500$22,414→ 2,043,024 total(indirect: By Xstelos Corp.)
Holdings
- 4,717,666(indirect: By Jonathan Couchman)
Common Stock, $0.01 par value
- 633,264(indirect: By Myrexis, Inc.)
Common Stock, $0.01 par value
Myrexis, Inc.
10% Owner
Transactions
- Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−57,500$22,414→ 2,043,024 total(indirect: By Xstelos Corp.) - Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−50,000$19,490→ 350,000 total(indirect: By Couchman Family Fund)
Holdings
- 633,264(indirect: By Myrexis, Inc.)
Common Stock, $0.01 par value
- 4,717,666(indirect: By Jonathan Couchman)
Common Stock, $0.01 par value
Xstelos Corp.
Other
Transactions
- Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−57,500$22,414→ 2,043,024 total(indirect: By Xstelos Corp.) - Sale
Common Stock, $0.01 par value
2021-08-13$0.39/sh−50,000$19,490→ 350,000 total(indirect: By Couchman Family Fund)
Holdings
- 633,264(indirect: By Myrexis, Inc.)
Common Stock, $0.01 par value
- 4,717,666(indirect: By Jonathan Couchman)
Common Stock, $0.01 par value
Footnotes (6)
- [F1]This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis") (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
- [F2]Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.
- [F3]Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
- [F4]Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
- [F5]Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
- [F6]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions and the reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commision, upon request, full information regarding the number of shares purchased at each separate price.
Documents
Issuer
ENZON PHARMACEUTICALS, INC.
CIK 0000727510
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001459450
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 6:07 PM ET
- Size
- 16.5 KB